AAAAAA

   
Results: 1-8 |
Results: 8
SAFETY AND COST-EFFECTIVENESS OF A 10 X 10(9) L TRIGGER FOR PROPHYLACTIC PLATELET TRANSFUSIONS COMPARED WITH THE TRADITIONAL 20 X 10(9)/L TRIGGER - A PROSPECTIVE COMPARATIVE TRIAL IN 105 PATIENTS WITH ACUTE MYELOID-LEUKEMIA/
Authors: WANDT H FRANK M EHNINGER G SCHNEIDER C BRACK N DAOUD A FACKLERSCHWALBE I FISCHER J GACKLE R GEER T HARMS P LOFFLER B OHL S OTREMBA B RAAB M SCHONROCKNABULSI P STROBEL G WINTER R LINK H
Citation: H. Wandt et al., SAFETY AND COST-EFFECTIVENESS OF A 10 X 10(9) L TRIGGER FOR PROPHYLACTIC PLATELET TRANSFUSIONS COMPARED WITH THE TRADITIONAL 20 X 10(9)/L TRIGGER - A PROSPECTIVE COMPARATIVE TRIAL IN 105 PATIENTS WITH ACUTE MYELOID-LEUKEMIA/, Blood, 91(10), 1998, pp. 3601-3606
A CASE OF ATYPICAL MYELODYSPLASTIC SYNDROME WITH MICROMEGAKARYOCYTES,NORMAL PLATELET COUNT, AND T(3-12)(Q21-P13) WITH INV(3)(Q21Q26)
Authors: SCHNITTGER S SCHOCH C STREUBEL B HINRICHS HF OTREMBA B PARWARESCH R FONATSCH C
Citation: S. Schnittger et al., A CASE OF ATYPICAL MYELODYSPLASTIC SYNDROME WITH MICROMEGAKARYOCYTES,NORMAL PLATELET COUNT, AND T(3-12)(Q21-P13) WITH INV(3)(Q21Q26), Genes, chromosomes & cancer, 20(3), 1997, pp. 292-298
G-CSF (LENOGRASTIM) AFTER CHEMOTHERAPY FOR ACUTE MYELOID-LEUKEMIA - APLACEBO-CONTROLLED RANDOMIZED TRIAL
Authors: LINK H WANDT H SCHONROCKNABULSI P EHNINGER G FRANKE A GACKLE R GEER T STROBEL G LINKESCH W KRIEGER O NIEDERWIESER D NIKIFORAKIS E OHL S OTREMBA B PITTERMANN E SCHMIDT H TISCHLER J WEISS J WILHELM M BADRI N
Citation: H. Link et al., G-CSF (LENOGRASTIM) AFTER CHEMOTHERAPY FOR ACUTE MYELOID-LEUKEMIA - APLACEBO-CONTROLLED RANDOMIZED TRIAL, Experimental hematology, 25(8), 1997, pp. 35-35
TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA WITH INTERFERON-ALPHA - A DECADE OF EXPERIENCE
Authors: FREUND M HEUSSNER P HILD F NOWAK R GROTEMETKE A DIEDRICH H KOCH O OTREMBA B VONWUSSOW P KLEINE HD MERAN J LINK H HINRICHS HF BALLEISEN L FONATSCH C POLIWODA H
Citation: M. Freund et al., TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA WITH INTERFERON-ALPHA - A DECADE OF EXPERIENCE, Medizinische Klinik, 91, 1996, pp. 18
IN AML IMMUNOPHENOTYPING IS IMPORTANT FOR DIAGNOSIS AND PROGNOSIS
Authors: GRAMATZKI M REPP R DIEHL S STROBEL G WANDT H LOFFLER B BODENSTEIN H SCHONROCK P SCHLIMOK G HEIDEMANN E OTREMBA B OHL S SCHNEIDER C EHNINGER G LINK H
Citation: M. Gramatzki et al., IN AML IMMUNOPHENOTYPING IS IMPORTANT FOR DIAGNOSIS AND PROGNOSIS, Blood, 88(10), 1996, pp. 2230-2230
G-CSF (LENOGRASTIM) AFTER CHEMOTHERAPY FOR ACUTE MYELOID-LEUKEMIA - APLACEBO-CONTROLLED TRIAL
Authors: LINK H WANDT H SCHONROCKNABULSI P EHNINGER G FRANKE A GACKLE R GEER T STROBEL G LINKESCH W KRIEGER O NIEDERWIESER D NIKIFORAKIS E OHL S OTREMBA B PITTERMANN E SCHMIDT H TISCHLER J WEISS J WILHELM M BADRI N
Citation: H. Link et al., G-CSF (LENOGRASTIM) AFTER CHEMOTHERAPY FOR ACUTE MYELOID-LEUKEMIA - APLACEBO-CONTROLLED TRIAL, Blood, 88(10), 1996, pp. 2654-2654
ALLOGENEIC BONE-MARROW TRANSPLANTATION COMPARED WITH HIGH-DOSE ARA-C POSTREMISSION THERAPY IN ACUTE MYELOID-LEUKEMIA
Authors: LINK H EHNINGER G",SCHONROCKNABULSI,GRAMATZKI,"FRANKE A EINSELE H TISCHLER J BRACK N OTREMBA B LUTZ M GACKLE R OHL S HEIDEMANN E WILHELM M LOFFLER B WEISS J GEER T DIEHL S WANDT H
Citation: H. Link et al., ALLOGENEIC BONE-MARROW TRANSPLANTATION COMPARED WITH HIGH-DOSE ARA-C POSTREMISSION THERAPY IN ACUTE MYELOID-LEUKEMIA, Blood, 88(10), 1996, pp. 2723-2723
COMBINATION OF CHEMOTHERAPY AND INTERFERON ALFA-2B IN THE TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA
Authors: FREUND M HILD F GROTEMETKE A NOWAK R OTREMBA B WORMANN B KOCH O DOHMEN M KLEINE HD LINK H HIDDEMANN W HINRICHS F BALLEISEN L FONATSCH C POLIWODA H
Citation: M. Freund et al., COMBINATION OF CHEMOTHERAPY AND INTERFERON ALFA-2B IN THE TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA, Seminars in hematology, 30(3), 1993, pp. 11-13
Risultati: 1-8 |